Back to Atlas
APotentially durableStandard research/education caution
CMP-0149
Approved oncology drug; senolytic use investigational
Venetoclax / ABT-199
Senolytic / BCL-2
Cell-type-dependent senolysis where BCL-2 dependence is high
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Selective BCL-2 inhibition
- Primary market use
- Oncology / senolytic research
Pharmacology
- Molecular weight (Da)
- 868.44
- Oral bioavailability
- Oral; food-enhanced
- Half-life
- ~16-26 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Clinical
- Clinical status
- Approved oncology drug; senolytic use investigational
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
More selective than navitoclax but senolytic utility is cell-type dependent